We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Sep 2021 - 25 Sep 2021

Blood Biomarkers Predict Likelihood of Castleman Disease Treatment Response

By LabMedica International staff writers
Posted on 13 Sep 2021
Print article
Image: High magnification micrograph of Castleman disease, hyaline vascular variant, also known as angiofollicular lymph node hyperplasia and giant lymph node hyperplasia (Photo courtesy of Wikimedia Commons)
Image: High magnification micrograph of Castleman disease, hyaline vascular variant, also known as angiofollicular lymph node hyperplasia and giant lymph node hyperplasia (Photo courtesy of Wikimedia Commons)
Biomarkers have been found in the blood that can be used to predict which patients with idiopathic multicentric Castleman disease are more likely to respond to siltuximab, the only [U.S.] Food and Drug Administration (FDA) approved treatment for the disorder.

Idiopathic multicentric Castleman disease (iMCD) is a subtype of the rare blood disorder, Castleman disease. This is a group of lymphoproliferative disorders characterized by lymph node enlargement, characteristic features on microscopic analysis of enlarged lymph node tissue, and a range of symptoms and clinical findings. People with iMCD have enlarged lymph nodes in multiple regions and often have flu-like symptoms, abnormal findings on blood tests, and dysfunction of vital organs, such as the liver, kidneys, and bone marrow. iMCD has features often found in autoimmune diseases and cancers, but the underlying disease mechanism is unknown. About 35% of iMCD patients die within five years of diagnosis.

Interleukin-6 (IL-6) is an established driver of iMCD in approximately one-third of patients. Siltuximab, a monoclonal antibody targeting IL-6, is the only medication approved by the FDA for the treatment of iMCD. Few options exist for siltuximab non-responders, and no validated tests are available to predict likelihood of response.

Investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA) sought to develop a test to predict likelihood that an iMCD patient would respond positively to siltuximab treatment.

For this work, the investigators analyzed blood samples from 88 iMCD patients and measured 1,178 blood proteins in each of those samples. The results were subsequently validated in an independent cohort of 23 iMCD patients. In addition, samples from 60 patients with clinico-pathologically overlapping diseases (human herpesvirus-8(HHV8)-associated Castleman disease, Hodgkin lymphoma, rheumatoid arthritis) and 44 healthy controls were analyzed for comparison.

Results revealed a cluster of seven blood proteins that was able to effectively predict the subgroup of patients who were most likely to respond to siltuximab.

“This discovery has the potential to improve precision medicine for iMCD - the concept that the right patient is given the right drug at the right time. Knowing which patients are likely to benefit from which drugs is a key piece of this puzzle," said senior author Dr. David Fajgenbaum, assistant professor of translational medicine and human genetics at the University of Pennsylvania School of Medicine.

The iMCD study was published in the August 26, 2021, online edition of the journal Blood Advances.

Related Links:
University of Pennsylvania School of Medicine

Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
IFA Automated Processor
Silver Supplier
Lipid Profile Analyzer
Cholestech LDX
Clinical Chemistry Analyzer
Mispa CXL Pro

Print article


Clinical Chem.

view channel
VIASURE HLA Celiac Real Time PCR Detection Kit

CerTest VIASURE HLA Celiac RT PCR Kit Enables Rapid Resolution of HLA Haplotypes Associated with Celiac Disease

CerTest Biotec (Zaragoza, Spain) has developed a simple and ready to use real-time PCR for the detection of the principal alleles of the HLA system and the subsequent determination of the DQ2 and DQ8 antigens... Read more


view channel

First-Of-Its Kind Blood Test to Distinguish between Bacterial and Viral Infections Using Body’s Immune Response Granted FDA Clearance

A first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes has been granted clearance by the US Food and Drug Administration (FDA).... Read more


view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.